NEW YORK CITY, NY / ACCESS Newswire / March 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

The global Clinical Trial Services Market, valued at US$60.76 billion in 2024, is forecasted to grow at a robust CAGR of 8.9% ...

TD Cowen analyst Charles Rhyee lowered the firm’s price target on Fortrea (FTRE) to $11 from $20 and keeps a Hold rating on the shares. The ...

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Fortrea Holdings Inc ...

Fortrea Holdings Inc. (NASDAQ:FTRE) Q4 2024 Earnings Call Transcript March 3, 2025 Fortrea Holdings Inc. misses on earnings expectations. Reported EPS is $0.18 EPS, expectations were $0.36.

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Fortrea Holdings Inc. (“Fortrea” or the “Company”) (NASDAQ: FTRE) on behalf of investors ...

Fortrea delivered weak fourth-quarter results, with sales and earnings falling significantly below expectations and shares declined 25%. Fortrea’s full-year net loss was $328.5 million, leading ...

Net Interest Expense: $21.9 million for Q4 2024, a decrease of $12.6 million year over year. Fortrea Holdings Inc (NASDAQ:FTRE) achieved a strong book-to-bill ratio of 1.35 in the fourth quarter, ...

Fortrea is a global, late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions.

Fortrea is guiding for revenue to drop this year after sales slipped and its loss widened in the fourth quarter, pressuring shares ahead of the opening bell. The contract-research organization ...

Ladies and gentlemen, thank you for standing by, and welcome to Fortrea Fourth Quarter 2024 Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference is being ...